Aptamer Details

Back to Search Results

LL4A (ID# 8244)

Transmembrane Protein CD63 (vemurafenib-resistant melanoma cells)
84.63 ± 13.04 nM (reported value)
Binding buffer: 0.1 mg/mL yeast tRNA (Sigma) and 1 mg/mL BSA (Sigma)added to washing buffer made up of Dulbecco’s PBS (DPBS; Thermo Fisher Scientific) supplemented with 4.5 mg/mL glucose glucose (Sigma) and 5 mM MgCl2 (Sigma)
NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.

Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.

Li, Hui et al. “A Novel Aptamer LL4A Specifically Targets Vemurafenib-Resistant Melanoma through Binding to the CD63 Protein.” Molecular therapy. Nucleic acids vol. 18 (2019): 727-738. doi:10.1016/j.omtn.2019.10.005

Have your aptamer oligo synthesized ORDER